Delta Air Lines Inc warned on Wednesday that new U.S. tariffs on Airbus planes “will inflict serious harm on U.S. airlines” and shrink the company’s profits.
Source:: Reuters – Business News
Newswire
- [ July 29, 2025 ] Aditxt’s (NASDAQ: ADTX) Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for Planned IPO Newsmakers
- [ July 29, 2025 ] Hoth Therapeutics (NASDAQ: HOTH) Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe Newsmakers
- [ July 23, 2025 ] Next Super Stock: Aditxt (NASDAQ: ADTX) = “Unicorn Farm” of Billion Dollar Healthcare Opportunities & Multiple Shots on Goal for +10X CEO Interview
- [ July 22, 2025 ] Snow Lake (NASDAQ: LITM) Acquires Strategic Stakes in Multiple U.S. Critical Minerals Projects Newsmakers
- [ July 22, 2025 ] Hoth Therapeutics (NASDAQ: HOTH) Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver – Side-by-Side Study vs. Semaglutide Begins Newsmakers
- [ July 18, 2025 ] Snow Lake (NASDAQ: LITM) Advances Uranium Projects in Wyoming and Namibia in Support of U.S. Policies on National & Energy Security Newsmakers
- [ July 11, 2025 ] Aditxt (NASDAQ: ADTX) Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization Newsmakers
- [ June 26, 2025 ] Hoth Therapeutics (NASDAQ: HOTH) HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects Newsmakers
- [ June 26, 2025 ] Lottery.com (NASDAQ: LTRY) Announces $10 Million Acquisition of GXR World Sports Assets to Power Global Launch of Sports.com Super App Newsmakers
- [ June 25, 2025 ] Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease. Healthcare
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.